JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation

Aberrant activation of epidermal growth factor receptor (EGFR) signaling is closely related to the development of non-small cell lung cancer (NSCLC). However, targeted EGFR therapeutics such as tyrosine kinase inhibitors (TKIs) face the challenge of EGFR mutation-mediated resistance. Here, we showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jing, Liu, Guiling, Qi, Hongyan, Xiang, Xueping, Shao, Jimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562424/
https://www.ncbi.nlm.nih.gov/pubmed/37813845
http://dx.doi.org/10.1038/s41419-023-06194-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562424/
https://www.ncbi.nlm.nih.gov/pubmed/37813845
http://dx.doi.org/10.1038/s41419-023-06194-0

Ejemplares similares